• Enrich Therapeutics has been awarded a Small Business Innovation Research(SBIR) phase 1 grant from National Institute of Health(NIH) in June 2019. The award will support our expedited development of disruptive single cell isolation platform as well as integrated novel applications.


  • ¬†Enrich Therapeutics has set up its new operation office/application development laboratory in BioCT Innovation Commons in July 2019. This new expansion would greatly benefit our business operation, investor relationship as well as facilitate our custom service launch in projected August 2019.

Leave a Reply

Your email address will not be published. Required fields are marked *